<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37790017</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma.</ArticleTitle><Pagination><StartPage>e44542</StartPage><MedlinePgn>e44542</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e44542</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.44542</ELocationID><Abstract><AbstractText>Multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) comprise a large fraction of hematologic malignancies diagnosed each year. However, the co-occurrence of these conditions in the same patient is rare. CD19- and B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapies have been approved in recent years with promising responses. Here, we present a patient who presented following a bone marrow biopsy that revealed MM with 20% lambda-restricted plasma cells with no evidence of lymphoma involvement in the marrow. A subsequent lymph node biopsy of a right thigh mass was done and revealed DLBCL. The patient received CD19-targeted CAR T-cell therapy and has no detectable MM or DLBCL. To our knowledge, this is the first case report in the literature describing a patient with concomitant MM and DLBCL who received CD19-targeted CAR T-cell therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023, D'Ovidio et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D'Ovidio</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciccolini</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalac</LastName><ForeName>Matko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osman</LastName><ForeName>Keren</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">car t-cell therapy</Keyword><Keyword MajorTopicYN="N">concomitant malignancies</Keyword><Keyword MajorTopicYN="N">diffuse large b-cell lymphoma</Keyword><Keyword MajorTopicYN="N">multiple myeloma</Keyword><Keyword MajorTopicYN="N">non-hodgkin&#x2019;s lymphoma</Keyword></KeywordList><CoiStatement>The authors have declared financial relationships, which are detailed in the next section.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>3</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37790017</ArticleId><ArticleId IdType="pmc">PMC10544703</ArticleId><ArticleId IdType="doi">10.7759/cureus.44542</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cancer statistics, 2020. Siegel RL, Miller KD, Jemal A. CA Cancer J Clin. 2020;70:7&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">31912902</ArticleId></ArticleIdList></Reference><Reference><Citation>The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Swerdlow SH, Campo E, Pileri SA, et al. Blood. 2016;127:2375&#x2013;2390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4874220</ArticleId><ArticleId IdType="pubmed">26980727</ArticleId></ArticleIdList></Reference><Reference><Citation>Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Blood. 2006;107:265&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895348</ArticleId><ArticleId IdType="pubmed">16150940</ArticleId></ArticleIdList></Reference><Reference><Citation>B cell lymphoma in association with multiple myeloma: analysis of the biologic relationship. Mahindra AK, Sohani AR, Toomey CE, et al. Blood. 2011;118:1590.</Citation></Reference><Reference><Citation>Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Liu Y, Chen X, Han W, Zhang Y. Drugs Today (Barc) 2017;53:597&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">29451276</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Locke FL, Ghobadi A, Jacobson CA, et al. Lancet Oncol. 2019;20:31&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6733402</ArticleId><ArticleId IdType="pubmed">30518502</ArticleId></ArticleIdList></Reference><Reference><Citation>Results from CARTITUDE- 1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM) Madduri D, Usmani SZ, Jagannath S, et al. Blood. 2019;134:577.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Idecabtagene vicleucel in relapsed and refractory multiple myeloma. Munshi NC, Anderson LD Jr, Shah N, et al. N Engl J Med. 2021;384:705&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">33626253</ArticleId></ArticleIdList></Reference><Reference><Citation>Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. Raje N, Berdeja J, Lin Y, et al. N Engl J Med. 2019;380:1726&#x2013;1737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8202968</ArticleId><ArticleId IdType="pubmed">31042825</ArticleId></ArticleIdList></Reference><Reference><Citation>International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. Lancet Oncol. 2014;15:0&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">25439696</ArticleId></ArticleIdList></Reference><Reference><Citation>Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. Palumbo A, Avet-Loiseau H, Oliva S, et al. J Clin Oncol. 2015;33:2863&#x2013;2869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846284</ArticleId><ArticleId IdType="pubmed">26240224</ArticleId></ArticleIdList></Reference><Reference><Citation>Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Cheson BD, Ansell S, Schwartz L, et al. Blood. 2016;128:2489&#x2013;2496.</Citation><ArticleIdList><ArticleId IdType="pubmed">27574190</ArticleId></ArticleIdList></Reference><Reference><Citation>Current concepts in the diagnosis and management of cytokine release syndrome. Lee DW, Gardner R, Porter DL, et al. Blood. 2014;124:188&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4093680</ArticleId><ArticleId IdType="pubmed">24876563</ArticleId></ArticleIdList></Reference><Reference><Citation>ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Lee DW, Santomasso BD, Locke FL, et al. Biol Blood Marrow Transplant. 2019;25:625&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">30592986</ArticleId></ArticleIdList></Reference><Reference><Citation>The acceleration of CAR-T therapy in non-Hodgkin lymphoma. Munshi PN, Ujjani C. Hematol Oncol. 2019;37:233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">30427551</ArticleId></ArticleIdList></Reference><Reference><Citation>Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. Philip T, Guglielmi C, Hagenbeek A, et al. N Engl J Med. 1995;333:1540&#x2013;1545.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477169</ArticleId></ArticleIdList></Reference><Reference><Citation>Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Vardhana SA, Sauter CS, Matasar MJ, et al.  https://doi.org/10.1111/bjh.14453. Br J Haematol. 2017;176:591&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556376</ArticleId><ArticleId IdType="pubmed">27982423</ArticleId></ArticleIdList></Reference><Reference><Citation>Recent updates on CAR T clinical trials for multiple myeloma. Lin Q, Zhao J, Song Y, Liu D. Mol Cancer. 2019;18:154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829852</ArticleId><ArticleId IdType="pubmed">31684964</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennsylvania Uo, Novartis: up-front CART-BCMA with or without huCART19 in high-risk multiple myeloma. 2018. https://ClinicalTrials.gov/show/NCT03549442 https://ClinicalTrials.gov/show/NCT03549442</Citation></Reference><Reference><Citation>Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. Feng D, Sun J. https://doi.org/10.1111/sji.12910 Scand J Immunol. 2020;92:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">32471019</ArticleId></ArticleIdList></Reference><Reference><Citation>Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nerreter T, Letschert S, G&#xf6;tz R, et al. Nat Commun. 2019;10:3137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6637169</ArticleId><ArticleId IdType="pubmed">31316055</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennsylvania Uo. CART-19 for multiple myeloma. 2014. https://ClinicalTrials.gov/show/NCT02135406 https://ClinicalTrials.gov/show/NCT02135406</Citation></Reference><Reference><Citation>Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy. Li T, Tan J, Chen L, et al. Medicine (Baltimore) 2020;99:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220358</ArticleId><ArticleId IdType="pubmed">32311967</ArticleId></ArticleIdList></Reference><Reference><Citation>Campo E, Nathwani BN, Pileri SA, Stein H, Jaffe ES, Muller-Hermelink HK. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Vol. 4. Lyon, France: IARC Publications; 2017. Nodal marginal zone lymphoma; p. 263.</Citation></Reference><Reference><Citation>Campo E, Nathwani BN, Pileri SA, Stein H, Jaffe ES, Muller-Hermelink HK. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Vol. 4. Lyon, France: IARC Publications; 2017. Plasmablastic lymphoma; p. 321.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>